TIB Molbiol

TIB Molbiol (TIB MOLBIOL Syntheselabor GmbH) is a German molecular diagnostics company based in Berlin. Founded in Berlin in 1990, it has spent more than three decades developing, manufacturing and supplying real-time PCR-based tests, primer/probe sets and key components used in medical diagnostics, research and industrial manufacturing worldwide. The company positions itself around three words — fast, precise, flexible — and describes its culture as pragmatic and unpretentious, "in true Berlin style." TIB Molbiol's product range centres on real-time PCR chemistry. Its LightMix® portfolio includes ready-to-use CE-IVD and Research Use Only (RUO) assays for detecting a wide range of targets, including human genetic mutations in cardiovascular, immune, hematological, digestive and neurological systems. LightMix® Modular assays let laboratories mix and match individual assays to build customised multiplex panels, from singleplex up to hexaplex in a single well. LightMix® OneTube assays combine all necessary components into one tube for LightCycler® systems, reducing contamination and pipetting errors. The company also supplies cobas® omni utility channel assays for cobas® systems, covering CE-IVD and RUO applications from pathogen detection to genetic mutation analysis. Beyond catalogue products, TIB Molbiol offers custom PCR in silico design services using TaqMan™ and SimpleProbe® technologies for applications such as detection, expression analysis, melting-curve genotyping and endpoint genotyping, as well as fully developed custom PCR kits for LightCycler® 480 and LightCycler® Pro instruments. Its LightSNiP assays use SimpleProbes® for melting-curve analysis of human single nucleotide polymorphisms (SNPs) based on NCBI rs numbers and gene names. In 2021 TIB Molbiol became part of the Roche Group. Within Roche it is known as the "speedboat" — a small, agile unit developing high-quality molecular diagnostic assays for platforms such as cobas® 5800/6800/8800, LightCycler® Pro and Digital LightCycler®. Roche's portfolio, expanded by the acquisition, includes over 70 CE-IVD assays and more than 250 research-use-only assays for LightCycler® and cobas® PCR systems, including tests for SARS-CoV-2 variants. The company has a track record of rapid response, developing and delivering molecular diagnostic solutions for global outbreaks within weeks. TIB Molbiol is led by Chief Executive Officer Dr. Marcus Droege, with Raphael Greiner as Head of Commercial & Services and Dr. Natalie Pauly as Head of Research & Development. The company continues to operate as a Berlin-based innovation driver within Roche, focused on real-time PCR diagnostics for laboratories and hospitals worldwide.

TIB Molbiol was founded in Berlin in 1990, at a time when the polymerase chain reaction (PCR) was transforming molecular biology and the first real-time PCR instruments were beginning to reach laboratories. From its Berlin base the company built its business around the chemistry that makes PCR work — primers, probes and the assay formats that turn a reaction into a reliable diagnostic test. Over more than 35 years it refined this focus, developing, manufacturing and supplying real-time PCR kits, primer/probe sets and key components used in medical diagnostics, research and industrial manufacturing worldwide. The company's identity grew around the LightMix® family of real-time PCR assays. LightMix® Kits were developed as ready-to-use CE-IVD and RUO solutions offering high sensitivity, specificity and accuracy across a wide range of targets, including human genetic mutations in cardiovascular, immune, hematological, digestive and neurological systems. LightMix® Modular assays extended this by allowing laboratories to mix and match individual assays into personalised multiplex panels, delivering reliable results from singleplex to hexaplex in one well. LightMix® OneTube assays combined all necessary components into a single tube for LightCycler® systems, minimising contamination and pipetting errors and reducing turnaround times. The company also developed LightSNiP assays using SimpleProbes® for melting-curve analysis of human single nucleotide polymorphisms based on NCBI rs numbers and gene names. Alongside catalogue products, TIB Molbiol built a custom design and development service. Its custom PCR in silico design offering uses TaqMan™ and SimpleProbe® technologies for applications such as detection, expression analysis, melting-curve genotyping and endpoint genotyping. The company also produces ready-to-use custom PCR kits for LightCycler® 480 and LightCycler® Pro instruments, performing assay design, wet-lab optimisation and verification, and quality control. A defining characteristic of TIB Molbiol has been rapid response to emerging threats. The company states that it has developed and delivered molecular diagnostic solutions for global outbreaks within weeks, helping laboratories and hospitals respond when timing is critical. This responsiveness became especially visible during the COVID-19 pandemic, when real-time PCR testing became a global priority and assays for SARS-CoV-2 and its variants were urgently needed. In 2021 TIB Molbiol became part of the Roche Group. The acquisition significantly expanded Roche's molecular diagnostics portfolio, which includes over 70 CE-IVD assays and more than 250 research-use-only assays for LightCycler® and cobas® PCR systems, by incorporating TIB Molbiol's range, including tests for SARS-CoV-2 variants. Within Roche, TIB Molbiol is known as the "speedboat" — a small, fast-moving unit developing high-quality molecular diagnostic assays for platforms such as cobas® 5800/6800/8800, LightCycler® Pro and Digital LightCycler®. It continues to operate from Berlin, combining what it describes as the agility of a biotech pioneer with the reach of a global healthcare leader, and remains a driver of innovation in the research and development of diagnostic solutions.

• 2021

  TIB Molbiol becomes part of the Roche Group.

• 1990

  TIB Molbiol founded in Berlin, Germany.

• Develops and delivers molecular diagnostic solutions for global outbreaks within weeks.

• Roche portfolio expanded to include over 70 CE-IVD assays and more than 250 research-use-only assays for LightCycler® and cobas® PCR systems, including SARS-CoV-2 variant tests.

Fast, precise, flexible real-time PCR diagnostics; an agile biotech "speedboat" within the Roche Group, combining biotech speed with global healthcare reach.

• LightMix® Kits

  Ready-to-use CE-IVD and RUO real-time PCR assays offering high sensitivity, specificity and accuracy for targets including human genetic mutations in cardiovascular, immune, hematological, digestive and neurological systems.

• LightMix® Modular Assays

  Flexible, customisable assays allowing users to mix and match different assays to create personalised multiplex panels, from singleplex to hexaplex in one well, for CE-IVD and RUO applications.

• LightMix® OneTube Assays

  RUO assays for LightCycler® Systems combining all necessary components into a single tube to minimise contamination and pipetting errors and reduce turnaround times.

• cobas® omni utility channel assays

  Assays designed for cobas® systems, offering CE-IVD and RUO solutions from pathogen detection to genetic mutation analysis, integrated with existing workflows.

• LightSNiP assays

  Assays using SimpleProbes® for melting-curve analysis of human single nucleotide polymorphisms (SNPs) based on NCBI rs numbers and gene names.

• Custom PCR in silico Design

  Design service using TaqMan™ and SimpleProbe® technologies for detection, expression analysis, melting curve genotyping and endpoint genotyping; starting price of 200 € for two primer sets and one probe.

• Custom PCR Kits

  Ready-to-use custom PCR kits for LightCycler® 480 and LightCycler® Pro instruments, containing pre-mixed primers, probes, positive control and Instructions for Use.

• Unconfirmed

  Reported2021.12.02

  Roche completes acquisition of TIB Molbiol[6]Roche完成收购TIB Molbiolpmlive.com

  Roche completed its share purchase agreement, acquiring all outstanding shares of TIB Molbiol Group. TIB Molbiol will operate as a subsidiary of Roche's Diagnostics division.

Read more

1. 1TIB Molbiol Syntheselabor GmbHtib-molbiol.com
2. 2Custom PCR Assay Design | TIB Molbioltib-molbiol.com
3. 3About TIB Molbiol – Pioneers in Real-Time PCR Diagnosticstib-molbiol.com
4. 4TIB Molbiol Leadership Team | Meet the Experts Behind Our Missiontib-molbiol.com
5. 5TIB Molbiolwikidata.org
6. 6Roche完成收购TIB Molbiolpmlive.com